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Pathognomonic features of advanced emphysema 
include a markedly reduced alveolar surface area due 
to the formation of blebs and bullae and significantly 
reduced elastic recoil of the lung.[1,2] Early airway 
closure occurs during expiration, with resultant air 
trapping and hyperinflation. Consequently, the range of expansion 
of preserved areas of lung tissue decreases. Furthermore, air trapping 
and hyperinflation place the diaphragm at a mechanical disadvantage 
owing to its flattened configuration. These processes in combination 
lead to refractory dyspnoea.[1] 
The aim of lung volume reduction (whether done surgically or 
endoscopically) is to achieve volume loss of the targeted, diseased region(s) 
and to redirect airflow to less affected areas.[2] This decreases dynamic 
hyperinflation, and improves diaphragmatic and chest wall mechanics. 
In theory, the remaining lung tissue has better elastic properties that can 
restore the outward radial pull on the small airways, thereby reducing 
airflow limitation. Reducing inhomogeneity of regional ventilation and 
perfusion may lead to improved ventilation/perfusion matching.
Lung volume reduction can in essence be achieved by either 
surgical or endoscopic techniques. This article aims to provide the 
practising general practitioner with an overview of the practical 
aspects of and current evidence for the use of the various techniques 
in South Africa (SA). The general indications and contraindications 
for lung volume reduction are summarised in Table 1. 
Lung volume reduction surgery 
Lung volume reduction surgery (LVRS) entails reducing the lung 
volume by wedge excision of emphysematous tissue. It is most often 
performed as a bilateral procedure, but occasionally as a unilateral 
one. Examples of the latter would include cases of severely 
asymmetrical emphysema, contralateral pleurodesis, contralateral 
thoracotomy and haemodynamic instability or massive air leak 
during the first side of a planned bilateral procedure. 
The National Emphysema Treatment Trial (NETT) is still the 
largest randomised trial of LVRS. It compared the benefits of LVRS 
with maximal medical therapy in >1 000 patients with advanced 
emphysema.[3] Within the first few months of starting the trial, a high 
risk of death (16% v. 0% controls) was identified in a subgroup of 
patients with a forced expiratory volume in 1 second (FEV1) <20% of 
predicted and either homogeneous emphysema or a diffusing capacity 
for carbon monoxide (DLCO) <20% of predicted. Patients with these 
characteristics were subsequently excluded from enrolment in NETT. 
Among patients without these high-risk characteristics, the 30-day 
mortality rate was 2.2% in the LVRS group, compared with 0.2% 
in the control group (p<0.001). At 2 years, total mortality among 
non-high-risk patients did not differ between the LVRS and medical 
therapy groups. The effect of LVRS on exercise capacity was modest, 
and the investigators concluded that LVRS does not confer a survival 
advantage over medical therapy. Only in a subgroup of patients with 
predominantly upper-lobe emphysema and low exercise capacity, was 
LVRS shown to reduce long-term mortality. 
There has been a significant decline in the number of LVRSs 
performed, both locally and internationally, mostly because of the 
modest benefit, strict selection criteria, morbidity and mortality 
associated with major thoracic surgery in patients with compromised 
pulmonary and cardiovascular reserves and the advent of endoscopic 
lung volume reduction (ELVR).[2] 
Endoscopic lung volume reduction 
Rationale 
The use of ELVR as a minimally invasive procedure with significantly 
lower morbidity and mortality than surgery is fast becoming a 
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new treatment modality for patients with 
severe emphysema. The objective is to 
reduce the risks and costs of surgery and 
also to achieve comparable physiological 
benefits. The procedure involves a standard 
endoscopic technique with endobronchial 
deployment of the device, which decreases 
the volume of the distal lung segments, 
thereby improving pulmonary mechanics and 
compliance.[2] By reducing airflow limitation and 
the work of breathing, the result is an almost 
instantaneous improvement in symptoms – most 
notably dyspnoea. The two most commonly 
used devices are endobronchial valves and 
coils.
Valves
One-way bronchial valve implantations 
have been available for use for over a 
decade, with the greatest clinical experience 
worldwide. Several clinical trials have been 
performed, leading to expanded knowledge 
and expertise with this technology, but the 
recently completed STELVIO-trial provided 
the strongest evidence for use of valves in 
patients without collateral ventilation.[4] 
Unidirectional valves allow one-way passage 
of air and secretions from the distal bronchus, 
thus preventing postobstructive infectious 
complications. By preventing the entrance of 
air during inspiration it causes atelectasis of 
the distal lung segments and a functional lung 
volume reduction. 
The success of the valves depends on 
whether there is complete collapse of the distal 
lung segments with the most severe disease, 
which is determined by two characteristics of 
emphysema, i.e. the degree of homogeneity and 
the presence of collateral ventilation. The valves 
are only effective if there is inhomogeneous 
emphysema as assessed on chest computed 
tomography (CT) scanning, either by visual 
inspection of the parenchyma or using 
specifically designed automated quantification 
software.[2] Furthermore, valves fail to induce 
collapse when the affected portion of the lung 
has collateral ventilation. This is a normal 
physiological phenomenon in many individuals, 
but significant interlobar collateral ventilation 
subverts the deflating effect of endobronchial 
blocking devices. Therefore, before placement 
of a valve, both homogeneous emphysema 
and collateral ventilation need to be excluded. 
Moreover, unilateral (compared with bilateral 
ELVR) valve placement was found to have a 
better outcome.[5-8] 
There are currently two commercially available 
devices available in SA: Zephyr endobronchial 
valves (Pulmonx Inc., USA, Fig. 1) and IBV 
intrabronchial valves (Olympus Respiratory 
America, USA, Fig. 2). Both devices are self-
expanding and delivered using a catheter that 
is introduced through the working channel of 
a flexible bronchoscope.[2] The most common 
reported adverse events experienced with 
endobronchial valve placement have been 
pneumothoraces (5 - 10%), mild haemoptysis 
(2 - 6%) and exacerbations of underlying chronic 
obstructive pulmonary disease (COPD) (8 - 
40%).[4-7]
Coils
While valves have been used for more than 
a decade, coils have only recently been 
introduced, with the first coils inserted 
in SA as recently as 2014. Coils (RePneu, 
BTG Inc., USA) are nitinol devices (Fig. 3) 
designed to be deployed into a straight airway, 
and thereafter to resume their preformed 
shape. This conformational shape change 
after deployment results in parenchymal 
retraction with associated volume loss, while 
maintaining airway patency.[9] The device 
is currently available in three lengths to 
accommodate different-sized airways. The 
coils are implanted via a flexible bronchoscope 
under general anaesthesia or conscious 
sedation and fluoroscopic guidance using a 
proprietary delivery system. Coils, in theory, 
not only cause lung volume reduction but 
also reduce airflow limitation by retensioning 
Table 1. General indications and contraindications for lung volume reduction
in patients with stable emphysema
Indications
40 - 75 years
Heterogeneous emphysema and no collateral ventilation* 
Dyspnoea despite maximal medical therapy and pulmonary rehabilitation 
FEV1 15 - 45%
Hyperinflation with TLC >100% and RV >150 - 175%
PaCO2 <6.7 kPa (50 mmHg)
PaO2 >6 kPa (45 mmHg) while breathing ambient air




>75% parenchymal destruction on HRCT†
Current smoking (last 6 months)
DLCO <20% (absolute for LVRS, relative for ELVR) 
Giant bullae (>1/3 of hemithorax) 
α1-antitrypsin deficiency
Previous thoracotomy, pleurodesis or chest wall deformity 
Excessive sputum
Severe pulmonary hypertension (>50 mmHg)
Active infection
Unstable cardiac conditions
Significant pleural or interstitial changes on HRCT
Any type of antiplatelet or anticoagulant therapy that cannot be discontinued for 7 days 
before a procedure
FEV1 = forced expiratory volume in 1 second; TLC = total lung capacity; RV = residual volume; PaCO2 = partial pressure of carbon dioxide; PaO2, = partial pressure of oxygen; 6MWD = 6-minute walking distance; DLCO = carbon monoxide diffusing capacity; LVRS = lung volume reduction surgery; ELVR = endoscopic lung volume reduction; HRCT = high-resolution computed tomography.
*Specific for endobronchial and intrabronchial valves.
†Specific for endobronchial coils.
Fig. 1. An endobronchial (Zephyr) valve. 
Fig. 2. An intrabronchial (IBV) valve. 
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the remaining airway network and tethering 
of the small airways, preventing collapse on 
expiration. 
Current evidence suggests that candidates 
with both heterogeneous and homogeneous 
emphysema can experience clinically 
significant benefit from ELVR using coils. 
This benefit is obtained regardless of 
the presence of collateral ventilation or 
complete lobar collapse after the proce dure. 
However, it requires that <25% of the total 
lung parenchyma be affected by radiological 
emphysema before insertion.[10,11] Approx imately 
75 - 80% of patients will experience minimal 
clinically important differences in lung function 
and quality of life, while mild haemoptysis 
of <5 mL (50 - 75%), exacerbations of 
COPD (5 - 12%), mild chest discomfort 
(15 - 50%) and infrequent pneumo thoraces 
(3%) are described as adverse events.[10,11] 
A recent report on the 3-year follow-up 
data of 38 patients who underwent ELVR 
using coils suggested that the treatment 
was safe; no late pneumothoraces, coil 
migrations or unexpected adverse events 
occurred.[12] Although clinical benefit gradually 
declined over time, 3 years after treatment 
approximately 50% of the patients main-
tained improvement in 6-minute walking 
distance, dyspnoea and quality of life scores. 
Other devices/procedures
Synthetic polymeric foam (Aeris Thera-
peutics Biological, USA) has been used 
to obtain atelectasis, but a recent study, 
which was prematurely terminated, raised 
some safety concerns.[13] This technology 
is currently not available in SA. Broncho-
scopic thermal vapour ablation (BTVA, 
Uptake Medical Corporation, USA) uses heated 
water vapour delivered to emphysematous 
lung parenchyma within a targeted region. 
The vapour induces an inflammatory 
reaction with subsequent fibrosis, result ing 
in lung volume reduction within 8 - 12 weeks. 
In a multicentre trial in Europe and Australia 
44 patients with severe upper-lobe-pre-
dominant emphysema were treated by 
unilateral BTVA in a single procedural 
setting – an effective treatment with associated 
clinical benefit independent of collateral 
ventilation.[14] 
Future of lung volume 
reduction in South 
Africa 
Current evidence suggests that not all 
classes and phenotypes of emphysema will 
benefit from ELVR, and that individual 
techniques may benefit different subgroups of 
patients.[6,9,10] Only a few centres in SA currently 
have the capacity to properly evaluate prospective 
candidates and potentially offer LVRS and/or 
ELVR in appropriate cases. The high cost of these 
interventions makes careful patient selection 
imperative to prevent wasteful insertion in those 
unlikely to gain clinical benefit. 
The initial screening for suitable candi-
dates should be performed at sub specialist 
(pulmo nologist) level in SA, and on 
patients with stable disease and no recent 
exacerbations. Routine special investigations 
should include high-resolution CT (to 
estimate heterogeneity, fissure integrity and 
degree of tissue destruction, and evaluate 
for possible underlying lung cancer), full 
pulmonary function testing, arterial blood 
gas sampling and echocardiography (to 
exclude pulmonary hypertension).[10] Lung 
volume reduction should not be offered to 
active smokers, patients with pulmonary 
hypertension, unstable cardiac pathology, 
active respiratory infections, very poor 
exercise tolerance, without clear evidence 
of hyperinflation, and those on antiplatelet 
or anticoagulant therapy that cannot 
be discontinued for 7 days prior to the 
procedure.[10,11,15] 
Appropriate or borderline candidates 
should be referred to a centre with the 
capacity to evaluate, treat and follow up, 
including the managing of complications 
related to LVRS or ELVR and removal of 
devices if required. 
Conclusion
A well-structured evidence-based approach 
to ELVR, including initial screening and 
subsequent referral to a specialised centre, 
is important to avoid inappropriate use 
of devices, which may be both wasteful 
and harmful. Appropriate candidates 
with marked hyperinflation and relatively 
preserved lung parenchyma are more likely 
to benefit from ELVR with bilateral coils, 
irrespective of the collateral ventilation and 
heterogeneity of the disease. By contrast, 
patients with heterogeneous disease and 
no collateral ventilation are more likely to 
benefit from unilateral ELVR with valves, 
aiming to achieve complete lobar collapse. 
LVRS should be reserved for patients with 
heterogeneous disease who have collateral 
ventilation and an acceptable operative risk 
profile. 
Both LVRS and ELVR are currently 
available in SA, but there are no head-to-
head studies comparing LVRS with ELVR 
or the various techniques and devices 
available to perform ELVR, and there are 
no official guidelines from any of the major 
thoracic societies. A task group of the 
Assembly on Interventional Pulmonology 
of the South African Thoracic Society has 
extensively reviewed all relevant publications 
and consulted international experts on 
the use of ELVR in SA in the form of local 
recommendations.[16] 
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Fig. 3. An endobronchial (RePneu) coil.
